COMMUNIQUÉS West-GlobeNewswire

Lifecore Biomedical Receives Accelerated Payment of Remaining $10 Million in Proceeds from Prior Equipment Sale
12/06/2025
Fortifies Balance Sheet and Reinforces Disciplined Capital Management Approach CHASKA, Minn., June 12, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR ) (“Lifecore”), a fully integrated contract [...]
Spring Bio Solution lance NCE Grid pour décoder les dépôts Para IV et les opportunités de premier déposant
12/06/2025
SOMERSET, New Jersey, 12 juin 2025 (GLOBE NEWSWIRE) -- Spring Bio Solution, l’un des leaders mondiaux de l’approvisionnement en comparateurs et en matériel pour essais cliniques , a lancé NCE Grid , une plateforme d’ [...]
ANI Pharmaceuticals Announces Presentation of New Preclinical Data
12/06/2025
The Use of Purified Cortrophin® Gel in Murine Collagen-Induced Arthritis Mouse Model presented as a poster at the European Alliance of Associations for Rheumatology (EULAR) 2025 Congress PRINCETON, N.J., June 12, 2025 ( [...]
Counslr Launches in Texas to Increase Access to Mental Health Support for Staff and Students
12/06/2025
Counslr Provides Unlimited Text-based Mental Health Support and Wellness Resources As Need Grows in Texas School Communities NEW YORK, June 12, 2025 (GLOBE NEWSWIRE) -- Counslr , a leading B2B mental health and wellness [...]
Positive PoNSTEP Study Results Presented at Consortium of Multiple Sclerosis Centers Annual Meeting
12/06/2025
-PoNS Therapeutic Experience Program (PoNSTEP) study demonstrates durable long-term beneficial effects of PoNS Therapy ® on gait deficit improvement in people with Multiple Sclerosis- -Presentation of full PoNSTEP study [...]
American Journal of Respiratory and Critical Care Medicine Publishes Landmark Data on AeroPace® System's Breakthrough Results in Ventilator Weaning
12/06/2025
International multi-center trial demonstrates AeroPace strengthens the diaphragm by 50%, weans more patients from ventilation, and reduces ventilator time by 3 days in patients difficult to wean from mechanical [...]
Syndax Presents New Revuforj® (revumenib) Data in Relapsed/Refractory mNPM1 and NUP98r Acute Leukemia from AUGMENT-101 Trial at EHA 2025
12/06/2025
– 26% (20/77) CR+CRh rate and 48% (37/77) ORR in efficacy-evaluable pivotal R/R mNPM1 AML population – – Robust responses observed across subgroups, regardless of co-mutations, number of prior lines of therapy, or prior [...]
I-Mab Regains Compliance with Nasdaq Minimum Bid Price Requirement
12/06/2025
ROCKVILLE, Md., June 12, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (“I-Mab” or the “Company”), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment [...]
Catheter Precision (VTAK) Reports Key Progress for the LockeT Product
12/06/2025
FORT MILL, S.C., June 12, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac [...]
BioNTech Announces Strategic Transaction to Acquire CureVac in Public Exchange Offer
12/06/2025
Acquisition will strengthen the research, development, manufacturing and commercialization of mRNA-based cancer immunotherapy candidates, marking BioNTech’s next key milestone in the execution of its oncology strategy [...]
New Prospective Cohort Study Reporting the Efficacy of Arrow™ Chlorhexidine-Impregnated Central Venous Catheters Demonstrates Reduced Infection Rates Among ICU Patients
12/06/2025
WAYNE, Pa., June 12, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced findings from a new multinational study reporting efficacy of Arrow™ [...]
Major shareholder announcement
12/06/2025
Pursuant to Section 30 of the Danish Capital Markets Act, Novonesis hereby announces that BlackRock, Inc. has notified Novonesis of the following status relating to the position of share capital attached to shares and [...]
MedRisk Welcomes Satish Narayanan as Chief Data Officer, Expanding Data and AI Capabilities
12/06/2025
KING OF PRUSSIA, Pa., June 12, 2025 (GLOBE NEWSWIRE) -- MedRisk, a leading managed care organization focused on improving recovery and cost outcomes in casualty claims, announced today the appointment of Satish [...]
Levicept to Present Further Analysis from Phase II Trial of Novel Neurotrophin-3 Inhibitor, LEVI-04, at EULAR
12/06/2025
Significant and clinically meaningful improvement in pain, function, and other outcomes in people with knee osteoarthritis Rapid onset of action observed Improvement in function out of proportion to pain-relieving [...]
Enterome raises $19 million to fund clinical development of its OncoMimics™ immunotherapy to treat Follicular Lymphoma
12/06/2025
Proceeds to fund Phase 1/2 trial of EO2463 OncoMimics™, as a monotherapy or in combination, to treat multiple forms of indolent non-Hodgkin lymphoma (iNHL) $9 million from new investor The Institute for Follicular [...]
Clariane completes its plan to strengthen its financial structure with the disposal of its Petits-fils home care services network
12/06/2025
Press release June 12 th , 2025 Clariane completes its plan to strengthen its financial structure with the disposal of its Petits-fils home care services network Paris, June 12 t h , 2025 – Clariane (CLARI.PA – ISIN [...]
Clariane finalise le plan de renforcement de sa structure financière avec la cession son réseau d’aide à domicile Petits-fils
12/06/2025
Communiqué de presse Clariane finalise le plan de renforcement de sa structure financière avec la cession de son réseau d’aide à domicile Petits-fils Paris, le 12 juin 2025 – Clariane (CLARI.PA – ISIN FR0010386334), [...]
Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in June
12/06/2025
Achieved 58% mean editing at five months after a single dose using high efficiency HSC delivery, demonstrating therapeutically relevant editing levels using a clinically validated strategy. Achievement supports [...]
Significant efficacy benefit of IMBRUVICA® (ibrutinib) plus venetoclax versus acalabrutinib plus venetoclax in frontline treatment of patients with chronic lymphocytic leukaemia suggested by indirect treatment comparison
12/06/2025
Cross-study findings indicate significant clinical benefit of frontline fixed-duration ibrutinib plus venetoclax with improved likelihood of undetectable minimal residual disease and progression-free survival versus [...]

Pages